Figure 1. Measles incidence showing increased inter-epidemic interval following introduction of measles vaccine, Chile, 1960-2008

Measles vaccine coverage for children <1 year of age until 1989 and aged 1 year thereafter.

Source: FCH/IM/PAHO.
Figure 2. Evolution of measles/rubella surveillance indicators, 1995-2005

<table>
<thead>
<tr>
<th>Year to Date - 1995</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Suspected Cases Under Investigation</td>
</tr>
<tr>
<td>Clinically</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Region</td>
<td>Country</td>
<td>% Sites Reporting Weekly</td>
<td>% Cases Investigated ≤48 Hours</td>
<td>% Cases W/ Complete Inves. Form</td>
</tr>
<tr>
<td></td>
<td></td>
<td>% Cases Adeq. Invest.</td>
<td>% Cases Adeq. Sample</td>
<td>% Lab. Recvd. ≤5 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td>% Lab Result ≤4 days</td>
<td>% Cases Discarded by Lab.</td>
<td>Number of Active Municipalities</td>
</tr>
</tbody>
</table>

Measles Surveillance Indicators for the period: 97/01 - 97/53

2000 Measles Surveillance Indicators for the period between weeks 01 to 52, 2000

2002 Measles Surveillance Indicators for the period between Weeks 01-52, 2002

Indicators of Integrated Measles/Rubella Surveillance for the Period Between Weeks 01-52, 2005

<table>
<thead>
<tr>
<th>Sub-region and Country</th>
<th>% Sites Reporting Weekly</th>
<th>% Cases Adequate Investigation</th>
<th>% Cases Adequate Sample</th>
<th>% Lab Received ≤5 days</th>
<th>% Lab Result ≤4 days</th>
<th>% Cases Discarded by Lab.</th>
<th>Chains of Transmission With Representative Samples for Viral Isolation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Measles</td>
</tr>
</tbody>
</table>
Figure 3. Integrated measles/rubella surveillance indicators, the Americas, 2003-2008

Source: FCH/IM/PAHO Annual Immunization Summary 2009
Figure 4. Rate of suspected measles/rubella cases per 100,000 population, Latin America and the Caribbean*, 2008

Rate per 100,000 population

- ≥2
- >1 - <2
- ≤ 1
- No case based surveillance or No or insufficient data reported

Data as of EW 10/2009
Source: Country reports FCH/IM/PAHO.
* Single rate for Caribbean countries reporting to CAREC.
Figure 5. Contribution of the Rubella Elimination Initiative to Maintaining Measles Elimination, The Americas

2003 & 2006 Directing Council Rubella Resolutions
 Calls Member States to:

(g) “eliminate rubella and congenital rubella syndrome from their countries by the year 2010”  
   44th DC, September 2003

(a) “implement policies and operational strategies to meet the rubella and CRS elimination target by 2010”  
   47th DC, September 2006
Figure 6. Measles elimination, the Americas, 1980-2009*

*Data until 8 August 2009; coverage data not available for 2009. **Prior to 1995, reported cases.
Figure 7. Number of reported measles deaths
Latin America and the Caribbean, 1990-2009

*2 deaths in 2004 due to subacute sclerosing panencephalitis

Source: FCH/IM/PAHO, data as of week 31, ending 8 August 2009.
Figure 8. Measles genotypes identified from case investigations in the Americas, 2001-2009*

Source Country reports to FCH/IM/PAHO and Global Measles Laboratory.
* Provisional data as of 18 August 2009.
Figure 9. Distribution of confirmed measles cases after the interruption of endemic transmission, the Americas, 2003-2009*

* Data as of week 31, ending 8 August 2009.

Source: Country reports to FCH/IM/PAHO.